HispanicBusiness

WEST PALM BEACH, FL and WASHINGTON, DC -- (Marketwire) -- 08/07/12 -- TNI BioTech, Inc. (PINKSHEETS: TNIB) announced today that the Company, under its joint venture agreement with GB Oncology and Imaging Group LTD ("GBOIG"), signed a letter of intent agreement to open and operate clinics for oncology and the treatment of HIV/AIDS and other infectious diseases in the Republic of Malawi, Africa.

The companies believe the clinics are an important step for TNIB as there is urgent need in Malawi for readily available, safe and effective treatments that can hopefully increase the life span and improve the quality of life of millions of HIV/AIDS and cancer patients. U.S. officials estimate about 1 in 10 Malawians is infected with HIV or has AIDS and the United Nations estimates approximately 23 million people in Sub-Saharan Africa are HIV positive. Sub-Saharan Africa accounts for only 12% of the global population, yet in 2010, 68% of all the people worldwide living with HIV resided in the Sub-Saharan Africa region. 70% of all new HIV infections are in sub-Saharan Africa and 90% of children living with HIV live in sub-Saharan Africa. Almost half of the deaths from AIDS-related illnesses in 2010 were in southern Africa.

The new government of the Republic of Malawi, under President Joyce Banda, a women's rights activist who has backed aggressive HIV prevention programs, signed an agreement with GBOIG, in partnership with TNIB, to provide treatments for HIV/AIDS, cancer and infectious diseases. TNIB, in partnership with GBOIG, seeks to deliver advanced treatments -- including safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives. At the same time, the clinics will support patients using TNI BioTech patented therapies to boost the immune system and improve quality of life. There are reasons for believing that an effective medical treatment already exists for preventing the HIV positive status from developing into full-blown AIDS. Low Dose Naltraxone (LDN) in clinical trials, both in the United States and Africa, has shown to be an effective immune system modulator, without significant toxic side effects, non-addicting and can be administered by a single capsule once daily at bedtime. IRT-103 (http://www.tnibiotech.com/products) (LDN) is also now available as a transdermal cream that is made for and is particularly effective with children suffering from a compromised immune system.

Dr. Gloria Herndon, Managing Member of GBOIG, said, "Though cultural mores change very slowly, we believe that IRT-103 (LDN) can serve to save literally millions of lives within a relatively short time at a cost of a $1.00 a day per person. This is in marked contrast to the $240 per dose for the antiretroviral drugs which must be taken several times a day, require a lot of medical supervision, and are notorious for toxic side effects and drug resistance in the patients who are fortunate enough to obtain them."

Noreen Griffin, CEO of TNIB, said, "When you understand that there are millions of victims of HIV/AIDS in Africa and only 37% of the people eligible for treatment in sub-Saharan Africa received antiretroviral drug treatment in 2009 because of economics, health personnel availability, and drug availability, we felt that something had to be done." TNIB has previously reached agreements to acquire the patents and research relating to IRT-103 (LDN), done by Dr. Bernard Bihari over the past 20 years, that demonstrate the effectiveness of this very inexpensive, non-addicting, non-invasive medication that is without significant toxic side effects.